Homepage - Cerus Corporate Site

Cerus Websites

“We really want to be a strong partner for our blood center customers in helping them deliver their important mission, which is to provide safe blood for patients.”

– William ‘Obi’ M. Greenman President and CEO, Cerus.

Pathogen Reduced Cryoprecipitated Fibrinogen Complex

Visit product website

INTERCEPT® Blood System for Platelets and Plasma

Visit US Site Visit International Site

At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe.

See Mission and Values

Annual Report

Annual Report 2021

Cerus’ Annual Meeting of Stockholders will be held online on Tuesday, June 3, 2025 at 9:00 a.m. Pacific Time.

Read More

Latest Press Releases

04/17/2025
Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

03/05/2025
Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

02/20/2025
Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

02/19/2025
Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference

2/7/2025
Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025

view all press releases

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.